PMCB
PharmaCyte Biotech Inc
NASDAQ: PMCB · HEALTHCARE · BIOTECHNOLOGY
$0.75
-1.32% today
Updated 2026-04-29
Market cap
$8.05M
P/E ratio
—
P/S ratio
12,904.41x
EPS (TTM)
$-0.89
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
PharmaCyte Biotech Inc (PMCB) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+61.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.2%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+2.5%
2025-12-31
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-17 | $-0.17 | — | $0.70 | $0.70 | -0.1% |
| 2025-12-31 | $-1.24 | — | $0.72 | $0.74 | +2.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-01-31 | $0.00 | $-0.17 | — | — | — |
| 2025-10-31 | $0.00 | $-1.24 | — | — | — |
| 2025-07-31 | $0.00 | $-1.23 | — | — | — |
| 2025-04-30 | $0.00 | $1.58 | — | — | — |
| 2025-01-31 | — | $-0.44 | — | — | — |
| 2024-10-31 | — | $-0.39 | — | — | — |
| 2024-07-31 | — | $1.90 | — | — | — |
| 2024-04-30 | — | $-0.32 | — | — | — |
| 2024-01-31 | $-0.07 | $-0.07 | +0.0% | — | — |
| 2023-10-31 | $-0.08 | $-0.26 | -222.0% | — | — |
| 2023-07-31 | $-0.07 | $-0.28 | -297.1% | — | — |
| 2023-04-30 | $-0.09 | $-0.01 | +91.7% | — | — |
Frequently asked questions
Has PharmaCyte Biotech Inc beaten earnings estimates?
PharmaCyte Biotech Inc has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports.
How does PMCB stock react to earnings?
PMCB stock has moved an average of +1.2% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.